Circio Holding ASA (OSL:CRNA) Total Liabilities: kr23.25 Mil (As of Dec. 2025)


OSL:CRNA Circio Holding ASA OSL:CRNA
27 GF Score
Price kr7.34
! 3 Warning Signs
View Full Analysis

What is Circio Holding ASA Total Liabilities?

Circio Holding ASA OSL:CRNA -0.27% 27 Total Liabilities is kr23.25 Mil as of Dec. 2025. GuruFocus rates OSL:CRNA with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Circio Holding ASA's Total Liabilities for the quarter that ended in Dec. 2025 was kr23.25 Mil.

Circio Holding ASA's quarterly Total Liabilities declined from Dec. 2024 (kr34.34 Mil) to Jun. 2025 (kr25.15 Mil) and declined from Jun. 2025 (kr25.15 Mil) to Dec. 2025 (kr23.25 Mil).

Circio Holding ASA's annual Total Liabilities declined from Dec. 2023 (kr124.25 Mil) to Dec. 2024 (kr34.34 Mil) and declined from Dec. 2024 (kr34.34 Mil) to Dec. 2025 (kr23.25 Mil).


Circio Holding ASA Total Liabilities Historical Data

* Premium members only.

The historical data trend for Circio Holding ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Circio Holding ASA Total Liabilities Chart

Circio Holding ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 147.54 97.85 124.25 34.34 23.25

Circio Holding ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 124.25 50.65 34.34 25.15 23.25
OSL:CRNA
27GF Score
Circio Holding ASA OSL:CRNA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Circio Holding ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Circio Holding ASA's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=10.756--12.492
=23.25

Circio Holding ASA's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=10.756--12.492
=23.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr23.25 Mil mean?
Circio Holding ASA (OSL:CRNA) has a Total Liabilities of kr23.25 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Circio Holding ASA and its competitors.
Is Circio Holding ASA's Total Liabilities too high?
Circio Holding ASA's current Total Liabilities is kr23.25 Mil. Overall, Circio Holding ASA has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Circio Holding ASA's Total Liabilities compare to VRTX and REGN?
Circio Holding ASA's Total Liabilities of kr23.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Circio Holding ASA and its competitors. Circio Holding ASA's current Total Liabilities is kr23.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Circio Holding ASA stock overvalued right now?
Circio Holding ASA (OSL:CRNA) has a current Total Liabilities of kr23.25 Mil. The current Total Liabilities is kr23.25 Mil. Circio Holding ASA's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Circio Holding ASA (OSL:CRNA), the current Total Liabilities is kr23.25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Circio Holding ASA Business Description

Other Exchanges 0RIS:UKTA50:Germany
Address c/o Mesh Community AS, Tordenskiolds Gate 2, Oslo, NOR, 0160
Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy applications. It has developed a circular RNA (circRNA) vector expression platform known as circVec, which is based on modular genetic constructs designed for circRNA production within target cells. The platform is being developed for applications including genetic medicine, cell therapy, and chronic disease treatment. The company's activities also include the development of RNA, DNA, and viral therapeutic technologies related to gene expression and protein production.
27GF Score

Get the complete analysis for OSL:CRNA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.34
Price